10-K: Qualis Innovations Inc. Reports Full Year 2023 Results Amidst Development Challenges

Qualis Innovations Inc. reports its full year 2023 results, highlighting a net loss and ongoing development of its SOLACE pain management device.

Summary

• Qualis Innovations Inc., a clinical stage company focused on pain management solutions, released its annual report for the fiscal year ended December 31, 2023.
• The company reported no revenue for both 2023 and 2022.
• Operating expenses decreased significantly to $230,241 in 2023 from $920,515 in 2022, primarily due to reduced stock-based compensation, consulting, and professional fees.
• The company experienced a net loss of $805,021 in 2023, compared to a net loss of $920,515 in 2022.
• A major factor contributing to the loss was an impairment of assets totaling $76,008 related to the SOLACE device development.
• The company's accumulated deficit reached $4,430,308 by the end of 2023.
• Qualis is developing the SOLACE device, a non-invasive pain management tool using electromagnetic induction, but has not yet finalized its development or generated any cash flow from it.
• The company is preparing to submit a 510(k) application to the FDA for clearance of the SOLACE device.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern due to recurring losses and a working capital deficit of $522,956.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with no revenue, significant losses, and an auditor's going concern warning. While there are some positive notes like reduced operating expenses, the overall outlook is negative from an investment perspective.

Positives

• Operating expenses were significantly reduced by 75% year-over-year.
• The net loss decreased from $920,515 in 2022 to $805,021 in 2023.
• The company is actively working towards FDA clearance for its SOLACE device.

Negatives

• The company has not generated any revenue for the past two fiscal years.
• The company recorded a significant impairment of assets related to the SOLACE device.
• The company has a substantial accumulated deficit of $4,430,308.
• Auditors have raised concerns about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and a working capital deficit.
• The company has not yet finalized the development of its SOLACE device and has not generated any cash flow from it.
• The company is dependent on obtaining FDA clearance for its SOLACE device to generate revenue.
• The company faces competition from larger medical device and pharmaceutical companies.
• The company may need to raise additional capital to fund its operations and development activities.
• The company experienced an impairment of assets due to issues with a third-party manufacturer.

Future Outlook

The company anticipates that its SOLACE device will be cleared by the FDA via the 510k process and that it will be deemed to be substantially equivalent to the identified predicate device. The company is also exploring various distribution models to maximize market reach. Management intends to raise additional funds by way of a public offering or an asset sale transaction.

Management Comments

• Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern.
• Management intends to raise additional funds by way of a public offering or an asset sale transaction.

Industry Context

The medical device industry is highly competitive, with rapid scientific advances. Qualis faces competition from major pharmaceutical companies, large and small medical device companies, universities, and research institutions. The company is focusing on a niche market of pain management devices that are not well-supported by larger companies.

Comparison to Industry Standards

• The company's lack of revenue is a significant deviation from industry norms for companies at a similar stage of development.
• The substantial reduction in operating expenses is a positive sign, but the company's overall financial position remains weak compared to industry benchmarks.
• The impairment of assets highlights the risks associated with medical device development and the challenges of bringing a product to market.
• The company's reliance on third-party manufacturers is common in the industry, but the issues experienced with the manufacturer highlight the importance of supply chain management.
• The company's focus on a niche market may provide a competitive advantage, but it also limits the potential market size.

Management Changes

Related Party Transactions

• The company borrows funds from the Companys CEO for working capital purposes from time to time.
• In January 2024, the Company issued a total of 10,000,000 common shares valued at $500,000 to two affiliates in settlement of a dispute.
• In January 2024, the Company issued 2,000,000 common shares to two (2) affiliates for aggregate gross proceeds of $100,000.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern issues.
• Employees are impacted by the company's limited resources and potential for restructuring.
• Customers may be affected by delays in product development and potential changes in the company's business strategy.
• Suppliers may face uncertainty due to the company's financial challenges.
• Creditors face increased risk due to the company's financial instability.

Next Steps

• The company plans to submit a 510(k) application to the FDA for clearance of the SOLACE device.
• The company intends to raise additional funds through a public offering or asset sale.
• The company will continue to evaluate acquisitions of and/or investments in products, technologies, capital equipment or improvements or companies that complement its business.

Key Dates

Keywords

SOLACE device, pain management, medical device, FDA clearance, electromagnetic induction, 510k application, financial results, going concern, impairment of assets, mPathix, Qualis Innovations